Clinical and Experimental Reproductive Medicine

  • 제33권2호
  • /
  • Pages.115-123
  • /
  • 2006
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지

GnRH (Gonadotropin-Releasing Hormone)에 의한 자궁내막암 유래 세포주의 세포 증식 억제 기전에 있어서 Integrin, FAK (Focal Adhesion Kinase) 및 ERK (Extracellular Signal Regulated Kinase)의 역할

Role of Integrin, FAK (Focal Adhesion Kinase) and ERK (Extracellular Signal Regulated Kinase) on the Suppressed Cell Proliferation of Endometrial Cancer Cells by GnRH (Gonadotropin-Releasing Hormone)

  • 최종락 (연세대학교 의과대학 진단검사의학교실) ;
  • 박동욱 (아주대학교 분자과학기술학과) ;
  • 최동순 (아주대학교 분자과학기술학과) ;
  • 민철기 (아주대학교 분자과학기술학과)
  • Choi, Jong Rak (Department of Clinical Pathology, Yonsei University) ;
  • Park, Dong Wook (Department of Molecular Science and Technology, Ajou University) ;
  • Choi, Dong Soon (Department of Molecular Science and Technology, Ajou University) ;
  • Min, Churl K. (Department of Molecular Science and Technology, Ajou University)
  • 발행 : 2006.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적: 본 연구를 통해 GnRH 의한 세포 분열의 억제는 integrin, FAK 빛 ERK를 통한 세포 내 신호전달 기전을 통하여 일어남을 규명하고자 하였다. 연구방법: 연구에 사용된 인간자궁내막암 세포주는 DMEM/F12 (10% FBS)의 조건에서 배양 하였다. GnRH-I과 -II는 실험 목적에 따라 100 nM 농도로 0, 5, 10, 15, 20, 30분간 또는 10 nM or 100 nM의 농도로 20분간 처리 하였다. 세포의 분열 정도는 [$^3H$] thymidine incorporation assay를 이용하여 정량적으로 측정 하였으며, Immunoblotting 방법을 이용하여 단백질의 발현을 확인 하였다. 결 과: GnRH-I과 -II 모두 HEC1A 세포의 세보분열을 억제하였으며 integrin ${\beta}3$의 발현을 증가 시켰다. GnRH-I과 -II를 처리 후 FAK 및 ERK의 안산화가 증가됨을 관찰할 수 있었다. 결 론: GnRH에 의한 세포분열의 억제는 integrin의 발현과 FAK 및 ERK의 인산화 과정을 통하여 일어남을 알 수 있었다.

Objective: To investigate new signal transduction cascade through integrin, FAK and ERK in the suppressed cell proliferation by GnRH-I and -II. Method: Human endometrial cancer cells (HEC1A) were cultured under the following condition: DMEM/F12 (10% FBS). GnRH-I and -II were treated time (0, 5, 10, 15, 20, 30 min; 100 nM) and dose (10 nM or 100 nM; 20 min) dependent manner according to experimental purposes. Cell proliferation was measured using [$^3H$] thymidine incorporation assay. Immunoblotting was utilized to detect proteins. Results: GnRH-I and -II inhibited proliferation of HEC1A cells and induced expression of integrin ${\beta}3$. Phosphorylation of FAK and ERK were induced by GnRH-I and -II. Conclusion: GnRH inhibited cell proliferation via the expression of integrin and FAK, ERK phosphorylation.

키워드

과제정보

연구 과제번호 : B-IT 융합 바이오 테크놀로지첨단화 사업

연구 과제 주관 기관 : 산자부

참고문헌

  1. Wierman ME, Bruder JM, Kepa JK. Regulation of gonadotropin-releasing hormone (GnRH) gene expression in hypothalamic neuronal cells. Cell Mol Neurobiol 1995; 15(1): 79-88 https://doi.org/10.1007/BF02069559
  2. Neill JD. GnRH and GnRH receptor genes in the human genome. Endocrinology 2002; 143(3): 737 -43 https://doi.org/10.1210/en.143.3.737
  3. Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis. J Obstet Gynaecol Res 2000; 26(5): 325-31 https://doi.org/10.1111/j.1447-0756.2000.tb01334.x
  4. Grimbizis G, Tsalikis T, Tzioufa V, Kasapis M, Mantalenakis S. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. Hum Reprod 1999; 14(2): 479-84 https://doi.org/10.1093/humrep/14.2.479
  5. Clayton RN, Catt KJ. Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function. Endocr Rev. 1981; 2(2): 186-209 https://doi.org/10.1210/edrv-2-2-186
  6. Wierman ME, Bruder JM, Kepa JK. Regulation of gonadotropin-releasing hormone (GnRH) gene expression in hypothalamic neuronal cells. Cell Mol Neurobiol 1996; 15(1): 79-88 https://doi.org/10.1016/S1569-2558(08)60301-X
  7. Huirne JA, Lambalk CB. Gonadotropin-releasinghormone-receptor antagonists. Lancet 2001; 358 (9295): 1793-803 https://doi.org/10.1016/S0140-6736(01)06797-6
  8. Limonta P, Moretti RM, Marelli MM, Motta M. The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol 2003; 24(4): 279 -95 https://doi.org/10.1016/j.yfrne.2003.10.003
  9. Clayton RN, Catt KJ. Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function. Endocr Rev 1981; 2(2): 186-209 https://doi.org/10.1210/edrv-2-2-186
  10. Schally A. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 1999; 20(10): 1247-62 https://doi.org/10.1016/S0196-9781(99)00130-8
  11. Schally A, Nagy A. Targeted cytotoxic analogs of luteinizing hormone-releasing hormone: a reply. Eur J Endocrinol 2001; 144(5): 559 https://doi.org/10.1530/eje.0.1440559
  12. Savino L, Baldini B, Susini T, Pulli F, Antignani L, Massi GB. GnRH analogs in gynecological oncology: a review. J Chemother 1992; 4(5): 312-20 https://doi.org/10.1080/1120009X.1992.11739184
  13. Santen RJ. Clinical review 37: Endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992; 75(3): 685-9 https://doi.org/10.1210/jc.75.3.685
  14. Luo X, Xu J, Chegini N. Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells. Reprod Biol Endocrinol 2003; 16: 125
  15. Meresman GF, Bilotas M, Buquet RA, Baranao RI, Sueldo C, Tesone M. Gonadotropin-releasing hormone agonist induces apoptosis and reduces cell proliferation in eutopic endometrial cultures from women with endometriosis. Fertil Steril 2003; 80(2): 702-7 https://doi.org/10.1016/S0015-0282(03)00769-6
  16. Kim KY, Choi KC, Park SH, Auersperg N, Leung PC. Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. J Clin Endocrinol Metab 2005; 90: 1670-7 https://doi.org/10.1210/jc.2004-1636
  17. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD, Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormonereleasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993; 77: 1458-64 https://doi.org/10.1210/jc.77.6.1458
  18. Noci I, Borri P, Bonfirraro G, Chieffi O, Arcangeli A, Cherubini A, et al. Longstanding survival without cancer progression in a patient affected by endometrial carcinoma treated primarily with leuprolide. Br J Cancer 2001; 85: 333-6 https://doi.org/10.1054/bjoc.2001.1900
  19. Davidson L, Pawson AJ, Millar RP, Maudsley S. Cytoskeletal reorganization dependence of signaling by the gonadotropin-releasing hormone receptor. J Biol Chem 2004; 279: 1980-93 https://doi.org/10.1074/jbc.M309827200
  20. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2: 91-100 https://doi.org/10.1038/nrc727
  21. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, et al. Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 2004; 64(3): 977-84 https://doi.org/10.1158/0008-5472.CAN-03-3056
  22. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002; 115(Pt 19): 3729-38 https://doi.org/10.1242/jcs.00071
  23. Lessey BA, Damjanovich L, Coutifaris C, Castelbaum A, Albelda SM, Buck CA. Integrin adhesion molecules in the human endometrium. Correlation with the normal and abnormal menstrual cycle. J Clin Invest 1992; 90(1): 188-95 https://doi.org/10.1172/JCI115835
  24. Lessey BA, Castelbaum AJ, Buck CA, Lei Y, Yowell CW, Sun J. Further characterization of endometrial integrins during the menstrual cycle and in pregnancy. Fertil Steril 1994; 62(3): 497-50 https://doi.org/10.1016/S0015-0282(16)56937-4
  25. Kanamori M, Vanden Berg SR, Bergers G, Berger MS, Pieper RO. Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multi forme. Cancer Res 2004; 64(8): 2751-8 https://doi.org/10.1158/0008-5472.CAN-03-3354
  26. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995; 9(9): 726-35 https://doi.org/10.1096/fasebj.9.9.7601337
  27. Del Pozo MA, Kiosses WB, Alderson NB, Meller N, Hahn KM, Schwartz MA. Integrins regulate GTPRae localized effector interactions through dissociation of Rho-GDI. Nat Cell Biol 2002; 4(3): 232-9 https://doi.org/10.1038/ncb759
  28. Hordijk PL, Verlaan I, van Corven EJ, Moolenaar WH. Protein tyrosine phosphorylation induced by lysophosphatidic acid in Rat-1 fibroblasts. Evidence that phosphorylation of map kinase is mediated by the Gi-p21ras pathway. J Biol Chem 1994; 269(1): 645-51
  29. Luttrell LM, Daaka Y, Della Rocca GJ, Lefkowitz RJ. G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat la fibroblasts. She phosphorylation and receptor endocytosis correlate with activation of Erk kinases. J Biol Chem 1997; 272(50): 31648-56 https://doi.org/10.1074/jbc.272.50.31648
  30. Kraus S, Naor Z, Seger R. Intracellular signaling path-ways mediated by the gonadotropin-releasing hormone (GnRH) receptor. Arch Med Res 2001; 32(6): 499-509 https://doi.org/10.1016/S0188-4409(01)00331-9
  31. Kim WH, Lee BL, Jun SH, Song SY, Kleinman HK. Expression of 32/67 -kDa laminin receptor in laminin adhesion-selected human colon cancer cell lines. Br J Cancer 1998; 77(1): 15-20
  32. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mech-anistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 2001; 98(6): 3352-7
  33. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Nati Acad Sci U S A 2002; 99(4): 2193-8
  34. Levi NL, Hanoch T, Benard O, Rozenblat M, Harris D, Reiss N, et al. Stimulation of Jun N-terminal kinase (JNK) by gonadotropin-releasing hormone in pituitary alpha T3-1 cell line is mediated by protein kinase C, c-Src, and CDC42. Mol Endocrinol 1998; 12(6): 815-24 https://doi.org/10.1210/me.12.6.815
  35. Subauste MC, Pertz O, Adamson ED, Turner CE, Junger S, Hahn KM. Vmculin modulation of paxillinFAK interactions regulates ERK to control survival and motility. J Cell Biol 2004; 165(3): 371-81 https://doi.org/10.1083/jcb.200308011